Altium Capital Management LLC Boosts Stake in Pulmonx Co. (NASDAQ:LUNG)

Altium Capital Management LLC boosted its position in shares of Pulmonx Co. (NASDAQ:LUNG - Free Report) by 63.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 815,000 shares of the company's stock after purchasing an additional 315,000 shares during the quarter. Pulmonx comprises about 1.6% of Altium Capital Management LLC's portfolio, making the stock its 23rd biggest position. Altium Capital Management LLC owned 2.06% of Pulmonx worth $5,534,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of LUNG. JPMorgan Chase & Co. raised its stake in Pulmonx by 2.4% in the third quarter. JPMorgan Chase & Co. now owns 1,055,522 shares of the company's stock worth $8,750,000 after buying an additional 25,002 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Pulmonx by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 902,240 shares of the company's stock worth $6,128,000 after purchasing an additional 9,454 shares during the last quarter. State Street Corp lifted its stake in shares of Pulmonx by 2.6% during the 3rd quarter. State Street Corp now owns 747,028 shares of the company's stock worth $6,193,000 after purchasing an additional 18,592 shares during the last quarter. Franklin Resources Inc. boosted its position in Pulmonx by 2.3% during the third quarter. Franklin Resources Inc. now owns 700,389 shares of the company's stock valued at $5,806,000 after purchasing an additional 15,570 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Pulmonx by 0.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 315,532 shares of the company's stock valued at $2,142,000 after purchasing an additional 2,363 shares during the last quarter. 91.04% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on LUNG. D. Boral Capital initiated coverage on shares of Pulmonx in a report on Monday, March 10th. They issued a "buy" rating and a $17.00 price target on the stock. Morgan Stanley initiated coverage on shares of Pulmonx in a report on Monday, March 10th. They issued an "equal weight" rating on the stock. Jefferies Financial Group started coverage on Pulmonx in a report on Monday, March 10th. They set a "buy" rating for the company. Finally, Citigroup initiated coverage on Pulmonx in a research note on Monday, March 10th. They set a "buy" rating on the stock. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $12.75.

Insider Buying and Selling at Pulmonx

In other Pulmonx news, Director Glendon E. French III sold 55,453 shares of Pulmonx stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $8.28, for a total value of $459,150.84. Following the completion of the transaction, the director now owns 1,011,974 shares of the company's stock, valued at approximately $8,379,144.72. The trade was a 5.20 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Geoffrey Beran Rose sold 5,779 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $7.13, for a total transaction of $41,204.27. Following the sale, the insider now directly owns 285,278 shares in the company, valued at approximately $2,034,032.14. The trade was a 1.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 145,660 shares of company stock worth $1,128,484. Insiders own 5.70% of the company's stock.

Pulmonx Stock Performance

Shares of LUNG stock traded up $0.13 during mid-day trading on Wednesday, reaching $4.89. The stock had a trading volume of 92,556 shares, compared to its average volume of 316,994. Pulmonx Co. has a 1-year low of $4.15 and a 1-year high of $10.01. The firm has a market cap of $196.81 million, a price-to-earnings ratio of -3.40 and a beta of 0.61. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. The business's fifty day moving average is $6.92 and its 200-day moving average is $6.64.

Pulmonx (NASDAQ:LUNG - Get Free Report) last issued its quarterly earnings results on Wednesday, February 19th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.12. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. The company had revenue of $23.77 million for the quarter, compared to the consensus estimate of $22.29 million. On average, research analysts forecast that Pulmonx Co. will post -1.55 earnings per share for the current year.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.